A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer

Trial Profile

A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Hearing loss
  • Focus Therapeutic Use
  • Sponsors Otonomy
  • Most Recent Events

    • 14 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2017.
    • 13 Sep 2017 Status changed from recruiting to discontinued according to an Otonomy media release.
    • 13 Sep 2017 According to an Otonomy media release, all development activities for OTIVIDEX have been suspended including termination of ongoing clinical trials and pre-registration support efforts.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top